$47.70
9.55% yesterday
Nasdaq, Nov 07, 10:05 pm CET
ISIN
US8342032005
Symbol
SLNO

Soleno Therapeutics Inc Stock price

$47.70
-14.41 23.20% 1M
-26.96 36.11% 6M
+2.75 6.12% YTD
-9.41 16.48% 1Y
+46.70 4,670.00% 3Y
+17.85 59.80% 5Y
-89.55 65.25% 10Y
-243.30 83.61% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+4.16 9.55%
ISIN
US8342032005
Symbol
SLNO
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$2.1b
Net debt
positive
Cash
$286.8m
Shares outstanding
50.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
71.6 | 16.0
EV/Sales
64.4 | 14.3
EV/FCF
negative
P/B
9.7
Financial Health
Equity Ratio
74.1%
Return on Equity
-71.7%
ROCE
-61.5%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$32.7m | $146.5m
EBITDA
$-189.6m | -
EBIT
$-191.6m | $-41.0m
Net Income
$-181.1m | $-38.5m
Free Cash Flow
$-84.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-169.6% | -
EBIT
-165.0% | 78.1%
Net Income
-177.9% | 78.1%
Free Cash Flow
-98.4%
Margin (TTM | estimate)
Gross
97.9%
EBITDA
-580.5% | -
EBIT
-586.7%
Net
-554.5% | -26.3%
Free Cash Flow
-259.3%
More
EPS
$-3.6
FCF per Share
$-1.7
Short interest
18.1%
Employees
92
Rev per Employee
$0.0
Show more

Is Soleno Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Soleno Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Soleno Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Soleno Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Soleno Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
33 33
-
100%
- Direct Costs 0.70 0.70
-
2%
32 32
-
98%
- Selling and Administrative Expenses 144 144
435% 435%
441%
- Research and Development Expense 74 74
78% 78%
227%
-190 -190
170% 170%
-580%
- Depreciation and Amortization 2.01 2.01
3% 3%
6%
EBIT (Operating Income) EBIT -192 -192
165% 165%
-587%
Net Profit -181 -181
178% 178%
-554%

In millions USD.

Don't miss a Thing! We will send you all news about Soleno Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Soleno Therapeutics Inc Stock News

Neutral
PRNewsWire
about 4 hours ago
SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist...
Neutral
PRNewsWire
about 13 hours ago
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing information about VYKAT™ XR, a once-daily oral tablet intended to treat hyperphagia.  Soleno has described this condition ...
Neutral
Seeking Alpha
3 days ago
Soleno Therapeutics, Inc. ( SLNO ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Anish Bhatnagar - Chairman, President, CEO & COO Meredith Manning - Chief Commercial Officer James MacKaness - CFO & Compliance Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, ...
More Soleno Therapeutics Inc News

Company Profile

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Head office United States
CEO Anish Bhatnagar
Employees 92
Founded 1999
Website soleno.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today